Medicine & pharmacy

Rubedo Life Sciences Announces First Patient Dosed with Lead Drug Candidate RLS-1496, the First GPX4 Modulator Targeting Pathologic Senescent Cells To Enter Phase 1 Clinical Trial

First patient dosed with topical RLS-1496 in clinical trial will assess the safety and clinical effects of single and multiple doses to treat adults with...

BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors

New data from SEQUOIA, to be reported in two oral presentations, underscore the benefits of BRUKINSA® as first-line treatment for patients with chronic lymphocytic leukemia...

Empowering Local Industry: SFI Health™ EMEA Commits to South African Packing Operations

Local manufacturer will take care of packing company’s key brands to make a difference in the community: Packed with Care, Packed right Here LUGANO, Switzerland–(BUSINESS...

CCM Biosciences presenteert gegevens over het First-In-Class AML-geneesmiddelenprogramma tijdens ASCO 2025

Het AML-geneesmiddelenprogramma van de onderneming is gericht op zowel nieuw gediagnosticeerde als recidief/refractaire FLT3-positieve AML, overwint de belangrijkste vormen van resistentie tegen door de FDA...

CCM Biosciences presenteert gegevens over het First-In-Class NSCLC-geneesmiddelenprogramma tijdens ASCO 2025

Het NSCLC-geneesmiddelenprogramma van de onderneming is gericht op het overwinnen van zowel mutationele als niet-mutationele resistentie tegen EGFR-remmers van de 3e generatie en presteert beter...

Merck Presents Positive Phase 2 Data for Enpatoran Demonstrating Reduction in Disease Activity in Patients with Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE) with Active Lupus Rash

Cohort analyses from the WILLOW study reveal clear proof of concept in patients with CLE and SLE with active lupus rash, showing clinically meaningful improvement...

Novotech Honored with Triple Win in 2025 Pharmaceutical Technology Excellence Awards

SYDNEY–(BUSINESS WIRE)– Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory partner for biotech and small- to mid-sized pharmaceutical companies, is proud...

iFIT Inc. betreedt markt voor connected Pilates met overname van Reform RX

PARK CITY, Utah–(BUSINESS WIRE)– iFIT Inc., een wereldleider in connected fitnessapparatuur en innovatie, heeft vandaag de overname aangekondigd van Reform RX, een toonaangevend bedrijf in...

CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 2025

Company’s AML drug program is focused on both newly diagnosed and relapsed/refractory FLT3-positive AML, overcoming major forms of resistance to FDA-approved FLT3 inhibitors, and outperforms...

CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 2025

Company’s NSCLC drug program is focused on overcoming both mutational and non-mutational resistance to 3rd-generation EGFR inhibitors and outperforms other investigational 4th-generation inhibitors in a...

Spinnaker Support kondigt nieuwe klanten aan nu de activiteiten van haar VMware-support in een stroomversnelling komen

-Spinnaker levert voortaan VMware-support aan verschillende nieuwe klanten, waaronder Quebec Airport, Telefónica Germany en Specsavers- -De afdeling VMware-support van Spinnaker blijft groeien nu organisaties op...

Spinnaker Support Announces New Customers as VMware Support Business Gathers Momentum

-Spinnaker now delivering VMware support for multiple new customers, including Quebec Airport, Telefónica Germany and Specsavers- -Spinnaker’s VMware support division continues to grow as organizations...

Fujirebio ontvangt marketinggoedkeuring voor Lumipulse® G pTau 217/β-amyloïde in-vitrodiagnostische test met plasmaverhouding van 1-42 als hulpmiddel bij het identificeren van patiënten met amyloïdepathologie geassocieerd met de ziekte van Alzheimer

—Eerste bloedgebaseerde in-vitro diagnostische test die FDA-goedkeuring krijgt voor patiënten die worden onderzocht op de ziekte van Alzheimer. — —Beschikbaarheid van nauwkeurige, toegankelijke, bloedgebaseerde diagnostische...

Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease

—First Blood-Based In-Vitro Diagnostic Test to Receive FDA Clearance for Patients Being Assessed for Alzheimer’s Disease. — —Availability of Accurate, Accessible, Blood-Based Diagnostic Tests Will...

IFF Announces Pricing of Tender Offers For Certain Outstanding Series of Notes

NEW YORK–(BUSINESS WIRE)– IFF (NYSE: IFF) announced today the Total Consideration (as defined below) payable in connection with its previously announced tender offers to purchase...